News

  • 23 August 2007

    EUSA Pharma Inc (“EUSA"), a transatlantic specialty pharmaceutical company focused on oncology, pain control and critical care, today announced the acquisition of the assets of Innocoll Inc ('Innocoll'). 

  • 27 June 2007

    PregLem today announced the closing of a CHF 32 million Series-A financing round (€20 million). The Series A financing round was led by Sofinnova Partners, and co-led by NeoMed Management and MVM Life Science Partners LLP. Concurrently, PregLem signed a licensing agreement with Ipsen (Euronext: IPN) under which Ipsen will grant PregLem worldwide development and commercialization rights to certain Ipsen compounds, for use in reproductive medicine only. The details of the agreement are not being disclosed. The funding will allow PregLem to undertake the development of these and other key compounds in the PregLem portfolio.

  • 1 March 2007

    EUSA Pharma announces the agreed acquisition of OPi SA (“OPi”), an integrated biopharmaceutical company. The acquisition will create a strong platform on which to build a significant transatlantic business. The acquisition is being funded with finance from a syndicate led by Essex Woodlands and 3i including, Goldman Sachs, advent Venture Partners, NeoMed and NovaQuest.

  • 3 November 2006

    Santhera Pharmaceuticals, a Swiss specialty pharmaceutical company with a focus on neuromuscular diseases, today announced that it has successfully completed its Initial Public Offering (IPO) of shares and its listing on the SWX Swiss Exchange.

  • 5 October 2006

    Santhera Pharmaceuticals, a Swiss specialty pharmaceutical company with a focus on neuromuscular diseases, announced today that it has successfully raised EUR 10 million with an option to call another EUR 5 million (in total CHF 24 million) in a private financing round. The oversubscribed funding was led by NGN Capital, one of Santhera's largest current shareholders. New investors in the round include NeoMed Management (Jersey), two equity funds managed by Schroder Investment Management (Luxembourg) SA and BioMedinvest (Switzerland). In addition, existing investors NGN Capital, Carnegie Asset Management, GIMV, Dow Chemical, Clariden Biotechnology Fund, 3i and private investors supported this round of financing.